An interventional study of Plant sterols 2g/day and Placebo in Cardiovascular Diseases, Hypercholesterolemia and Prediabetic State, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by University of Valencia · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with LDL-cholesterol values > 115 mg/dl and not pharmacologically treated participants treated with the PS-containing food supplement or placebo supplement.
Cardiovascular disease (CVD) is the leading cause of death worldwide, with hypercholesterolemia being one of the main risk factors for CVD. The deposition and oxidation of LDL-cholesterol particles triggers a series of molecular events favoring chronic low-grade inflammation, endothelial dysfunction and oxidative stress. This situation promotes atherogenesis thus increasing cardiovascular risk. Obesity favors the secretion of pro-inflammatory mediators and promotes the recruitment of macrophages to adipose tissue, insulin resistance, hyperglycemia and hyperlipidemia, thus increasing the risk of CVD. In addition, obesity has been associated with gut dysbiosis, which in turn is associated with atherosclerosis in some studies. Beneficial effects of PS on LDL-cholesterol and inflammatory, endothelial dysfunction and oxidative stress markers have been reported by several clinical trials. A meta-analysis suggests a lowering effect of PS on body mass index (BMI) in participants with BMI>25. Furthermore, the consumption of PS has been beneficially associated in in vitro studies with changes in intestinal microbial profile, sterol metabolism and short chain fatty acids (SCFA) production. Therefore, the hypothesis is if the consumption of PS as a food supplementation could reduce cardiovascular risk. The present study aims to evaluate the LDL-cholesterol serum levels after regular intake of a food supplement containing PS (2 g/day) in overweight/obese type 1 or 2 patients, normoglycemic /pre-diabetic and with LDL-cholesterol values > 115 mg/dl not pharmacologically treated. This is a crossover study with 21 participants (intake of a food supplement containing PS) and 21 participants (intake of excipient-based placebo), with a first intervention period of 8 weeks. After a 6-week washout period, the treatments are switched, with a second intervention period of 8 weeks. In addition, to the LDL-cholesterol lowering assessment, other biochemical, hematological, inflammatory, endothelial dysfunction and oxidative stress parameters are assessed in serum samples. Moreover, sterol and metabolite profiling in serum and feces, microbiota modulation, anthropometric measurements and body composition, bioimpedance, dietary intake and physical activity questionnaire are evaluated. All parameters are evaluated at the beginning (weeks 0 and 14) and at the end of each intervention period (weeks 8 and 22).
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 42 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →University of Valencia is the lead sponsor of 357 studies on the registry; 75 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day)
Dietary Supplement: Plant sterols 2g/day
Sachet containing the powdered excipients of the dietary supplement
Dietary Supplement: Placebo
Drug page: PhytosterolsStudies of PhytosterolsPhytosterols pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
Sachet containing the powdered excipients of the dietary supplement during 8 weeks
Changes in plasmatic LDL-c
LDL-c, calculated by the Friedewald's formula, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic total cholesterol
Total cholesterol, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic HDL-c
HDL-c, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic non-HDL cholesterol
Non-HDL cholesterol, calculated by subtracting HDL-c from total cholesterol, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic triglycerides
Triglycerides, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic Apo A
Apo A, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic Apo B
Apo B, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic fibrinogen
Fibrinogen, assessed by Clauss coagulometric method, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic High-sensitivity C-reactive protein (hsCRP)
hs CRP, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic glucose
Glucose, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic insulin
Insulin, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of each period the intervention
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
HOMA-IR, calculated by mathematical formula from the fasting insulin and fasting glucose levels, with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum levels of the sterols and metabolites profile
Profile sterols and metabolites, assessed by gas chromatography coupled with flame ionization detector (GC-FID), with repeated measures (at the beginning and at the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in feces levels of the sterols and metabolites profile
Profile sterols and metabolites, assessed by gas chromatography coupled with flame ionization detector (GC-FID), with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum interleukin 10 (IL-10)
IL-10, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum interleukin 12p70 (IL-12p70)
IL-12p70, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum interleukin 1β (IL-1β)
IL-1β, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum interleukin 6 (IL-6)
IL-6, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum interleukin 8 (IL-8)
IL-8, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum tumor necrosis factor alpha (TNFα)
TNFα, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum vascular cell adhesion molecule-1 (VCAM-1)
VCAM-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum E-Selectin
E- Selectin, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in serum endothelin (ET-1)
ET-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention
Time frame: 0, 8, 14 and 22 weeks
Changes in serum plasminogen activator inhibitor-1(PAI-1)
PAI-1, assessed by immunochemical techniques, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic LDL-cholesterol oxidation
LDL-cholesterol oxidation, assessed by enzyme kits, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic 8-isoprostane
8-isoprostane, assessed by enzyme kits, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic malondialdehyde (MDA)
MDA, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention
Time frame: 0, 8, 14 and 22 weeks
Changes in reduced glutathiones (GSH)
GSH, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in oxidized glutathione (GSSG)
GSSG, assessed by ultra-performance liquid chromatography-MS (UPLC-MS), with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in the composition of microbiota in feces
Composition of microbiota, assessed by genetic sequencing and subsequent biostatistical analysis, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in feces of short-chain fatty acids (SCFAs)
SCFAs, assessed by high-performance liquid chromatography with an ultraviolet detector (HPCL-UV), with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in plasmatic levels of cholesterol oxidation products (COPs)
COPs, assessed by gas chromatography-mass spectrometry, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in body weight (WT)
WT, assessed by standard balance scale, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in body height (HT)
HT, assessed by tape measure, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in body circumferences
Circumferences, assessed by tape measure, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Changes in Bioelectrical impedance analysis (BIA)
BIA, assessed by bio-impedance meter, with repeated measures (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Assessment of dietary intake
Food frequency survey Questionnaire (FFQ) is used, consisting in 136 questions divided into the different food groups (dairy products; eggs, meat and fish; vegetables; fruit; pulses and cereals; oils and fats; bakery and confectionery; miscellaneous; drinks) indicating the average frequency of consumption during the past year, which can be scored as never or almost never, per month (1-3), per week (1, 2-4,5-6), per day (1, 2-3, 4-6, 6+), with repeated of questionnaire (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Evaluation of the physical activity to measure quality of life
International physical activity questionnaire-short form (IPAC-SF) is used, consisting in 7 questions. Intensity, frequency and duration of the exercise are evaluated through metabolic equivalent of task (METs). This allows to differentiate 3 levels of physical activity: Low: Not enough activity to achieve the next level Moderate: 3 or more days of vigorous physical activity for at least 20 minutes per day, 5 or more days of moderate physical activity and/or walking at least 30 minutes per day, or 5 or more days of any combination of walking, moderate or vigorous physical activity achieving at least a total of 600 METs. High: Vigorous physical activity at least 3 days per week achieving a total of a least 1500 METs, or 7 days of any combination of walking, with moderate and/or vigorous physical activity, achieving a total of a least 3000 METs. With repeated of questionnaire (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Evaluation of the Mediterranean diet adherence to measure quality of life
Mediterranean diet adherence screener (MEDAS) is used, consisting in 14 questions (each one 0 or 1 point, final score between 0 and 14). Results are ranged between 0-7 points (low adherence), 7-10 (moderate adherence), and 10-14 (high adherence) With repeated of questionnaire (at the beginning and the end of each period the intervention)
Time frame: 0, 8, 14 and 22 weeks
Plan to share: No
Started May 2024 (actual). Primary completion is estimated for Dec 2024, 7 months after the start.
Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 7 months is below that.
Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phytosterols